SMO and Down syndrome: As promising examples, treatments with SAG restored partially cerebellar morphology and behavioral deficits in a Down Syndrome mouse model (Roper et al., 2006; Das et al., 2013), and purmorphamine, a Smo agonist, ameliorated behavioral and cellular alterations in a rat model of ASD (Rahi et al., 2021).